Sanjay Gupta, MD
Psychiatry · Cheektowaga, NYNPI 1740238906
Payments from drug & device makers
Across 2,096 payments — averaging $887.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$404K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$393K
- Johnson & Johnson$240K
- Alkermes, Inc.$183K
- Otsuka America Pharmaceutical, Inc.$179K
- Vanda Pharmaceuticals Inc.$135K
- plus $326K from 24 others
What the payments were for
- Consulting fees$82,3044%
- Speaking & faculty fees$1,540,22083%
- Travel & lodging$196,96811%
- Food & beverage$39,4582%
- Education$2110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 508 | $403,811 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 334 | $392,541 |
| Johnson & Johnson | 308 | $239,911 |
| Alkermes, Inc. | 191 | $182,666 |
| Otsuka America Pharmaceutical, Inc. | 192 | $179,347 |
| Vanda Pharmaceuticals Inc. | 123 | $135,223 |
| Teva Pharmaceuticals USA, Inc. | 88 | $90,536 |
| Acadia Pharmaceuticals Inc | 73 | $65,706 |
| AbbVie(2 entities) | 116 | $65,521 |
| E.r. Squibb & Sons, L.L.C. | 46 | $42,834 |
| Indivior Inc. | 32 | $37,279 |
| Sunovion Pharmaceuticals Inc. | 49 | $20,116 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 6 | $2,666 |
| Eisai Inc. | 2 | $140 |
| Neuronetics, Inc. | 3 | $133 |
| Janssen Scientific Affairs, LLC | 1 | $131 |
| Axsome Therapeutics, Inc. | 2 | $130 |
| Avanir Pharmaceuticals, Inc. | 4 | $83 |
| Idorsia Pharmaceuticals US Inc | 1 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $72 |
| Stryker | 1 | $42 |
| Merck | 2 | $39 |
| Lundbeck LLC | 2 | $37 |
| Arbor Pharmaceuticals, Inc. | 1 | $30 |
| Almatica Pharma LLC | 1 | $26 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Noven Therapeutics, LLC | 1 | $17 |
| AstraZeneca | 1 | $14 |
| Shire North American Group Inc | 1 | $13 |
| Neurology Practice Consortium GPO, LLC | 3 | $0 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$719,708
- INGREZZA$394,165
- CAPLYTA$388,141
- SPRAVATO$235,501
- ARISTADA INITIO$179,927
- Fanapt$134,187
- REXULTI$108,786
- UZEDY$88,482
- ABILIFY MAINTENA$71,384
- NUPLAZID$64,776
- VRAYLAR$64,054
- PERSERIS$36,980
- ABILIFY ASIMTUFII$32,827
- COBENFY$27,628
- LATUDA$19,564
- LYBALVI$452
- INVEGA SUSTENNA$242
- VIIBRYD$200
- ONGENTYS$119
- Leqembi$119
How this compares
$1,859,160 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 20 | $153,296 |
| CaplytaLumateperone Tosylate | 64 | $102,976 |
| AustedoDeutetrabenazine | 17 | $102,532 |
| Abilify AsimtufiiAripiprazole | 12 | $69,936 |
| AristadaAripiprazole Lauroxil | 20 | $68,400 |
| Invega SustennaPaliperidone Palmitate | 13 | $45,797 |
| TrintellixVortioxetine Hydrobromide | 53 | $26,300 |
| RexultiBrexpiprazole | 13 | $18,719 |
| Lurasidone Hcl | 29 | $2,425 |
| Buspirone Hcl | 138 | $1,944 |
| Duloxetine Hcl | 86 | $1,439 |
| Vilazodone Hcl | 15 | $1,290 |
| Ziprasidone Hcl | 15 | $1,284 |
| Quetiapine Fumarate | 52 | $888 |
| Lithium Carbonate ErLithium Carbonate | 73 | $850 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $403,811 | $153,29620 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $392,541 | $102,97664 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $90,536 | $102,53217 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Asimtufii, Rexulti | $179,347 | $88,65525 claims |
| Alkermes, Inc.Aristada | $182,666 | $68,40020 claims |
| Johnson & JohnsonInvega Sustenna | $239,911 | $45,79713 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $72 | $26,30053 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in Cheektowaga
- Elyssa BarronWhite Plains$12.8M
- Mark DibuonoStaten Island$11.9M
- Ronald BrennerHempstead$11.5M
- Anton PorsteinssonRochester$7.6M
- Michael LiebowitzNew York$7.1M
- Leslie CitromePomona$5.7M
- John KaneGlen Oaks$4M
- Inna Yuryev-GolgerBrooklyn$3M
- Subhdeep VirkBuffalo$3M
- Paul EderNew York$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.